Regenerative medical devices company Tissue Regenix Group plc (AIM: TRX) revealed on Monday that it has received approval from the Irish Health Products Regulatory Authority (HPRA) to establish a logistics hub in Ireland for distributing its allograft products within the European Union (EU). The HPRA approval ensures compliance with relevant standards and legislation for health products.

Additionally, Tissue Regenix has entered an exclusive distribution agreement with Spineart España SLU for the distribution of its allograft products in Spain. Spineart, a medical device company operating globally, focuses on providing safe and efficient solutions to spine surgeons and patients.

Tissue Regenix is known for its patented decellularisation technology (dCELL), addressing clinical needs in sports medicine, foot and ankle injuries and wound care.

The company's acquisition of CellRight Technologies in August 2017 expanded its expertise in regenerative medicine, particularly in spine, trauma, orthopaedic, dental and ophthalmological surgical procedures.